Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 109,200 shares at a total cost of HKD 582,300 [1] - The buyback price per share ranges from HKD 5.32 to HKD 5.34 [1] - The buyback is scheduled for November 11, 2025 [1]

Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - The company plans to repurchase 109,200 shares at a total cost of HKD 582,300 [1] - The buyback price per share ranges from HKD 5.32 to HKD 5.34 [1] Financial Implications - The total expenditure for the buyback represents a strategic investment in the company's own equity, potentially enhancing shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on November 10, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 9.753 million shares for a total of 43.2831 million yuan, representing 0.919% of its total share capital [2]. - China Merchants Industry Holdings (01919) repurchased 3 million shares for 42.5626 million yuan, accounting for 0.562% of its total share capital [2]. - Sinopec Limited (00386) repurchased 4.072 million shares for 17.7963 million yuan, which is 0.110% of its total share capital [2]. Group 2: Other Notable Buybacks - Yimai Sunshine (N23020) repurchased 929,000 shares for 14.9596 million yuan, representing 0.712% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.31 million shares for 7.4321 million yuan, which is 4.518% of its total share capital [2]. - Gushengtang (02273) repurchased 250,000 shares for 7.4123 million yuan, accounting for 3.541% of its total share capital [2].

Core Viewpoint - Weigao Co., Ltd. has been actively repurchasing its shares, indicating a strategy to support its stock price amid recent declines [2][3]. Share Buyback Activity - On November 10, Weigao repurchased 682,000 shares at a price range of HKD 5.300 to HKD 5.420, totaling HKD 3.6511 million [2]. - The stock closed at HKD 5.370 on the same day, reflecting a decrease of 0.92%, with a total trading volume of HKD 152 million [2]. - Since November 6, the company has conducted buybacks for three consecutive days, acquiring a total of 1.2176 million shares for a cumulative amount of HKD 6.5485 million, during which the stock price fell by 1.65% [2]. Year-to-Date Buyback Summary - Year-to-date, Weigao has executed 76 buybacks, acquiring a total of 23.8008 million shares for a total expenditure of HKD 133 million [3]. - The detailed buyback data shows various dates, share quantities, and price ranges, indicating a consistent buyback strategy throughout the year [3][4][5].

Core Viewpoint - Weigao International Holding Corporation Pte. Ltd. has entered into a joint venture agreement with PT Oneject Indonesia to establish Oneject Wego Medical in Indonesia, focusing on local production of medical consumables [1][2] Group 1: Joint Venture Details - The joint venture will be owned 45% by Weigao International and 55% by the joint venture partner [1] - The joint venture will manufacture and sell intravenous catheters, infusion sets, and other medical consumables, targeting products that are currently heavily imported into Indonesia [1] - The partner, PT Oneject Indonesia, is a subsidiary of GDK Company, a leading manufacturing and sales group in Indonesia, which will provide extensive resources and market knowledge [1] Group 2: Strategic Benefits - The establishment of the joint venture is expected to allow the company to enter emerging overseas markets, expand its customer base, and create synergies with existing operations [2] - The board believes that the joint venture aligns with the overall interests of the company and its shareholders [2]

Core Viewpoint - Weigao International Holding Corporation Pte. Ltd. has entered into a joint venture agreement with PT Oneject Indonesia to establish Oneject Wego Medical in Indonesia, aiming to manufacture and sell medical consumables locally, reducing reliance on imports [1][2] Group 1: Joint Venture Details - The joint venture will be owned 45% by Weigao International and 55% by the joint venture partner [1] - The joint venture will not consolidate its financial performance into the company's accounts [1] - The business activities will focus on manufacturing and selling intravenous catheters, infusion sets, and other medical consumables in Indonesia [1] Group 2: Strategic Rationale - The establishment of the joint venture is expected to allow the company to enter emerging overseas markets and expand its customer base [2] - The joint venture is anticipated to create synergies with the company's existing operations [2] - The board believes that the joint venture aligns with the overall interests of the company and its shareholders [2] Group 3: Partner Profile - The joint venture partner is a subsidiary of GDK Company, a leading manufacturing and sales group in Indonesia [1] - The partner specializes in producing standard syringes, safety and smart auto-disable syringes, blood bags, dialysis products, and blood collection tubes [1] - The partner's established resources, network, and market knowledge will help identify suitable opportunities in the Indonesian market [1]

Core Viewpoint - Weigao Group has established a joint venture in Indonesia to manufacture and sell medical consumables, aiming to reduce reliance on imports and expand its market presence [1][2] Group 1: Joint Venture Details - Weigao International Holding Corporation Pte. Ltd. will hold a 45% stake in the joint venture, Oneject Wego Medica, while the local partner, PT Oneject Indonesia, will hold 55% [1] - The joint venture will focus on the production of intravenous catheters, infusion sets, and other medical consumables, emphasizing localized manufacturing [1] Group 2: Strategic Implications - The establishment of the joint venture is expected to allow the company to enter emerging overseas markets, expand its customer base, and create synergies with existing operations [2]

Core Viewpoint - Weigao Group (01066.HK) announced a share buyback on November 10, spending HKD 3.6511 million to repurchase 682,000 shares at a price range of HKD 5.30 to HKD 5.42 per share [1] Summary by Category Company Actions - The company executed a buyback of 682,000 shares, indicating a commitment to enhancing shareholder value [1] - The total expenditure for the buyback was HKD 3.6511 million, reflecting the company's financial strategy [1] Share Price Information - The repurchase price per share ranged from HKD 5.30 to HKD 5.42, which may suggest the company's valuation perspective on its own shares [1]

Group 1 - The company, Weigao Group (01066), announced a share buyback on November 10, 2025, spending HKD 3.65114 million to repurchase 682,000 shares [1]